Potential depot medroxyprogesterone acetate-triggered torsades de pointes in a case of congenital type 2 long QT syndrome.
Department of Medicine, Division of Cardiovascular Diseases, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota 55905, USA.
John R
JR
Giudicessi
Brian C
BC
Brost
Kyle D
KD
Traynor
Michael J
MJ
Ackerman
D000328:Adult; D003271:Contraceptive Agents, Female / Q000009:adverse effects*; D017147:Defibrillators, Implantable; D003692:Delayed-Action Preparations; D005260:Female; D006329:Heart Conduction System / Q000503:physiopathology; D006801:Humans; D055103:Hypodermoclysis; D007273:Injections, Intramuscular; D008133:Long QT Syndrome / Q000151:congenital / Q000235:genetics / Q000503:physiopathology; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular; D011256:Pregnancy Outcome; D011374:Progesterone / Q000502:physiology; D011475:Prosthesis Failure; D017180:Tachycardia, Ventricular / Q000209:etiology; D016171:Torsades de Pointes / Q000139:chemically induced* / Q000150:complications* / Q000503:physiopathology
D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D011374:Progesterone; D017258:Medroxyprogesterone Acetate